A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer

NCT07035353 | Not Yet Recruiting

• 1 other identifier: TDXD2025
• Study Type: observational
• Target: 200
• Locations: 0 countries
• Sites: N/A

Brief Summary

The study is an open, prospective study to collect data on the efficacy and safety of T-DXd (DS8201) in Chinese patients with HER2 overexpressing and HER2 underexpressing advanced breast cancer in actual clinical practice in China. Cohort A: HER2 overexpressing patients with advanced breast cancer Cohort B: HER2 underexpressing patients with advanced breast cancer A total of 400 subjects will be enrolled in the program, with 200 enrolled in Cohort A and 200 enrolled in Cohort B. The study will be conducted by a physician in accordance with current clinical practice. The treatment plan will be recommended to the subjects by the treating physician based on the current clinical practice guidelines in conjunction with the clinical practice, and the patient's decision to be treated with T-DXd (DS8201) should precede enrollment in this study. Because of the non-interventional nature of this study, this study does not alter or interfere with clinician treatment decisions, and the actual medical practice of patients. Inclusion in the study after the first treatment with the drug is based on inclusion/exclusion criteria. Subject enrollment in this study should be within 2 months of the subject's first dose of medication and prior to the first efficacy assessment. Demographic data, past medical and treatment history, ECOG score, vital signs + physical examination, laboratory tests, objective tumor evaluation, coadministration/concomitant therapy, adverse events, time to progression/death, and subsequent antitumor therapy were collected at baseline, during treatment, and at subsequent follow-up. Imaging evaluation was performed according to RECIST 1.1 criteria. Adverse events evaluation criteria were based on NCI-CTCAE version 5.0.

Conditions

HER2 Overexpression; Advanced Stage Breast Cancer; Low Expression of HER2

Outcome Measures

Primary Outcomes (1)

• To assess progression-free survival (PFS) of Chinese patients with advanced breast cancer with HER2 overexpression and HER2 underexpression treated with real-world T-DXd (DS8201).

  through study completion, an average of 1 year

Study Arms (2)

HER2 overexpression in advanced breast cancer patients

Drug: T-DXd (DS8201) 5.4 mg/kg, IVD, 1 cycle every 21 days.

Patients with advanced breast cancer with low HER2 expression

Drug: T-DXd (DS8201) 5.4 mg/kg, IVD, 1 cycle every 21 days.

Interventions

T-DXd (DS8201) 5.4 mg/kg, IVD, 1 cycle every 21 days. DRUG

The treatment plan will be recommended to the subject by the treating physician in accordance with current clinical practice guidelines and clinical practice, and the patient's decision to receive T-DXd (DS8201) should precede enrollment in this study. The strategy for administering a particular treatment to a subject is not determined a priori by the trial protocol, but should be in accordance with current clinical practice. Because of the non-interventional nature of this study, this study does not alter or interfere with the patient's actual current medical practice.

HER2 overexpression in advanced breast cancer patients; Patients with advanced breast cancer with low HER2 expression

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients receiving T-DXd (DS8201) for HER2 overexpression and HER2 underexpression advanced breast cancer in actual clinical practice in China Chinese patients

You may qualify if:

• Must be competent and able to sign and date an Institutional Review Board (IRB) or Ethics Committee (EC)-approved ICF prior to any study-specific procedure or trial.
• Female patients aged ≥18 years with advanced breast cancer who are adults.
• Pathologically confirmed breast cancer that meets the following criteria:
• unresectable or metastatic, with evidence of recurrent or metastatic disease.
• HER2 overexpression, or HER2 hyperexpression as determined by the central laboratory in accordance with the American Society of Clinical Oncology-Society of American Pathologists guidelines.
• Patients must have measurable lesions according to RECIST 1.1 criteria.
• Unmenopausal, menopausal, and perimenopausal female patients were allowed to be enrolled.
• Prior antitumor therapy against recurrent metastatic disease is allowed.

You may not qualify if:

• Early stage breast cancer
• Patients who do not meet the criteria for HER2 overexpression and HER2 underexpression.
• Female patients during pregnancy or lactation.
• Patients deemed unsuitable for enrollment by the investigator.

Sponsors & Collaborators

• Tianjin Medical University Cancer Institute and Hospital: lead

MeSH Terms

Interventions

trastuzumab deruxtecan; Isovaleryl-CoA Dehydrogenase

Intervention Hierarchy (Ancestors)

Oxidoreductases Acting on CH-CH Group Donors; Oxidoreductases; Enzymes; Enzymes and Coenzymes

Central Study Contacts

Weixin Sun

CONTACT

(022)65150123-8212; scarcity0@outlook.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 12, 2025
• First Posted: June 25, 2025
• Study Start: June 30, 2025
• Primary Completion (Estimated): May 1, 2028
• Study Completion (Estimated): May 1, 2035
• Last Updated: June 25, 2025

Record last verified: 2025-04